A.SH. FAKHRUTDINOVA, A.V. SINEGLAZOVA

 Kazan State Medical University, Kazan

Contact details:

Fakhrutdinova A.Sh. — Assistant Lecturer of the Department of Primary Care and General Practice

Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-987-230-46-70, e-mail: aliyazak@mail.ru

 The purpose — to evaluate the impact of treatment adherence on blood pressure and lipid profile changes in young adults.

Material and methods. 94 patients, including 45 males (47.9%) and 49 females (52.1%), with a median age of 33[28.7–38] years were prospectively studied for 18.6[17.4–20.1] months. Adherence was evaluated using the Questionnaire for Quantitative Assessment of Treatment Adherence (KOP-25) with lifestyle modifications (PM), drug therapy (PT), medical support (PS), and general treatment adherence (PL). Clinical examination, medical records review, and lipid profile analysis were performed. The following cardiometabolic risk factors were evaluated: blood pressure (BP) ≥ 130/85 mmHg, hypercholesterolemia (HCS), decreased high-density lipoprotein cholesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), hypertriglyceridemia (HTG), and non-HDL cholesterol. Lipitension was defined as a combination of elevated BP and any dyslipidemia.

Results. At baseline, 22.3% of patients had elevated BP, 7.4% hypertension, 73.4% dyslipidemia, and 16% lipitension. During follow-up, significant reductions in the prevalence of elevated BP, elevated LDL-C, and elevated non-HDL-C were observed. The average systolic BP increased in individuals with low general treatment adherence (GA), low/moderate lifestyle modification (LM) adherence, low pharmacotherapy (PT) adherence, and low and moderate medical support (MS). Mean HDL-C levels increased in participants with low PT adherence and low/moderate MS. Individuals with low/moderate GA had higher odds of BP ≥ 130/85 mmHg, diastolic BP ≥ 85 mmHg, lipitension, and hypertriglyceridemia compared to those with high GA.

Conclusion. Low adherence levels were associated with increased systolic BP and non-HDL-C. Young individuals with low adherence had higher odds of elevated BP and lipitension compared to those with high adherence.

Key words: adherence, arterial hypertension, dyslipidemia, lipitension, KOP-25 questionnaire.

REFERENCES

1. Mensah G.A., Fuster V., Murray C.J.L., Roth G.A. Global burden of cardiovascular diseases and risks collaborators. Global burden of cardiovascular diseases and risks, 1990–2022. J. Am. Coll. Cardiol, 2023, vol. 82 (25), rr. 2350–2473. DOI: 10.1016/j.jacc.2023.11.007
2. Grinshteyn Yu.I., Shabalin V.V., Ruf R.R. et al. Prehypertension in Krasnoyarsk Krai: prevalence, relationship with sociodemographic and cardiometabolic risk factors. Kardiovaskulyarnaya terapiya i profilaktika, 2019, vol. 18, no. 2, pp. 52–57 (in Russ.). DOI: 10.15829/1728-8800-2019-2-52-57
3. Sineglazova A.V., Fakhrutdinova A.Sh., Kim T.Yu. et al. Lipitencia and cardiometabolic risk factors in young age. Rossiyskiy kardiologicheskiy zhurnal, 2024, vol. 29, no. 4, p. 5888 (in Russ.). DOI: 10.15829/1560-4071-2024-5888
4. Cosentino F., Verma S., Ambery P. et al. Cardiometabolic risk management: insights from a European Society of cardiology cardiovascular round table. Eur. Heart J, 2023, vol. 44 (39), rr. 4141–4156. DOI: 10.1093/eurheartj/ehad445
5. Nikolaev N.A., Martynov A.I., Skirdenko Yu.P. et al. International Declaration on Commitment to Treatment 2023 (“Omsk Declaration”): presentation for Russian readers. Meditsinskiy vestnik Severnogo Kavkaza, 2024, vol. 19, no. 1, pp. 1–9 (in Russ.). DOI: 10.14300/mnnc.2024.19001
6. Loprinzi P.D., Branscum A., Hanks J. et al. Healthy lifestyle characteristics and their joint association with cardiovascular disease biomarkers in US adults. Mayo Clin. Proc, 2016. DOI: 10.1016/j.mayocp.2016.01.009
7. Li Y., Pan A., Wang D.D. et al. Impact of healthy lifestyle factors on life expectancies in the US population. Circulation, 2018. DOI: 10.1161/CIRCULATIONAHA.117.032047
8. Lv J., Yu C., Guo Y. et al. Adherence to a healthy lifestyle and the risk of type 2 diabetes in Chinese adults. Int. J. Epidemiol, 2017, vol. 1, is. 46 (5), rr. 1410–1420. DOI: 10.1093/ije/dyx074.
9. Shal’nova S.A., Maksimov S.A., Balanova Yu.A. et al. Adherence to a healthy lifestyle in the Russian population depending on the socio-demographic characteristics of the population. Kardiovaskulyarnaya terapiya i profilaktika, 2020, vol. 19, no. 2, p. 2452 (in Russ.). DOI: 10.15829/1728-8800-2020-2452
10. Drapkina O.M., Livzan M.A., Martynov A.I. et al. The first Russian consensus on the quantitative assessment of adherence to treatment: basic provisions, algorithms and recommendations. Meditsinskiy vestnik Severnogo Kavkaza, 2018, vol. 13, no. 1.2, pp. 259–271 (in Russ.). DOI: 10.14300/mnnc.2018.13039
11. Balanova Yu.A., Gomanova L.I., Evstifeeva S.E. et al. Profilaktika v skhemakh i tablitsakh: uchebno-metodicheskoe posobie [Prevention in diagrams and tables: a teaching aid]. Moscow: ROPNIZ, OOO “Silitseya-Poligraf”, 2023. 52 p. DOI: 10.15829/ROPNIZ-b1-2023
12. Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2024. Rossiyskiy kardiologicheskiy zhurnal, 2024, vol. 29, no. 9, p. 6117 (in Russ.). DOI: 10.15829/1560-4071-2024-6117
13. Shlyakhto E.V., Nedogoda S.V., Konradi A.O. et al. The concept of new national clinical guidelines on obesity. Rossiyskiy kardiologicheskiy zhurnal, 2016, vol. 4, pp. 7–13 (in Russ.). DOI: 10.15829/1560-4071-2016-4-7-13
14. Erina A.M., Rotar’ O.P., Orlov A.V. et al. Prehypertension and cardiometabolic risk factors (based on the ESSE-RF study). Arterial’naya gipertenziya, 2017, vol. 23, no. 3, pp. 243–252 (in Russ.). DOI: 10.18705/1607-419X-2017-23-3-243-252
15. Fedulaev Yu.N., Karseladze N.D., Evdokimov F.A. et al. The role of adherence in the prevention of arterial hypertension. Meditsinskiy alfavit. Seriya “Arterial’naya gipertenziya i komorbidnost’”, 2019, vol. 2, no. 30 (405), pp. 28–32 (in Russ.). DOI: 10.33667/2078–5631–2019–2–30(405)-28–32
16. Boytsov S.A., Karpov Yu.A., Logunova N.A. et al. Ways to increase adherence to antihypertensive therapy. Rossiyskiy kardiologicheskiy zhurnal, 2022, vol. 27, no. 9, p. 5202 (in Russ.). DOI: 10.15829/1560-4071-2022-5202
17. Shal’nova S.A., Oganov R.G., Deev A.D. et al. Combinations of coronary heart disease with other non-communicable diseases in the adult population: associations with age and risk factors. Kardiovaskulyarnaya terapiya i profilaktika, 2015, vol. 14, no. 4, pp. 44–51(in Russ.). DOI: 10.15829/1728-8800-2015-4-44-51
18. Sumarokov A.B. Non-adherence to treatment in hyperlipidemia — a risk factor for cardiovascular disease? Kardiologicheskiy vestnik, 2021, vol. 16, no. 1, pp. 28–33 (in Russ.). DOI: 10.17116/Cardiobulletin20211601128
19. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J, 2018, vol. 39, pp. 3021–3104. DOI: 10.1093/eurheartj/ehy339
20. Gorokhova T.V., Perepech N.B. Possibilities of using combination therapy in patients with a combination of arterial hypertension and dyslipidemia. Rossiyskiy kardiologicheskiy zhurnal, 2022, vol. 27, no. 7, p. 5132 (in Russ.). DOI: 10.15829/1560-4071-2022-5132